Lon S. Schneider on No Pony in There: Bapi Fails Mild to Moderate ApoE4 Carriers
COMMENT The topline results of the Phase 3, bapineuzumab trial 302 are disappointing but not surprising. That is mainly because the prior Phase 2, 201 trial was a multiple ascending dose trial, not planned as an efficacy trial, and didn’t show reliable efficacy e